Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology

The most widely used approach in the immunotherapy treatment of cancer is the administration of monoclonal antibodies directed against regulatory molecules of immune control that inhibit the activation of T cells, the so-called check point inhibitors (ICI). ICI nephrotoxicity epidemiology and pathol...

ver descrição completa

Detalhes bibliográficos
Autores: Alonso, F, de Francisco, ALMM, Auñón, P, García-Carro, C, García, P, Gutiérrez, E, Macía, M, Quintana, LF, Quiroga, B, Soler, MJ, Torregrosa, I
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2023
País:España
Recursos:INCLIVA
Repositório:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p18084
Acesso em linha:https://incliva.portalinvestigacion.com/publicaciones/18084
Access Level:Acceso aberto
Palavra-chave:Acute kidney injury
Acute interstitial nephritis
Immune checkpoint inhibitors
Immunotherapy
Renal immune-related adverse
effect
Renal transplantation
id ES_71f2cf97c81ee214610d9dab62eafc7f
oai_identifier_str oai:incliva.fundanetsuite.com:p18084
network_acronym_str ES
network_name_str España
repository_id_str
spelling Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of NephrologyAlonso, Fde Francisco, ALMMAuñón, PGarcía-Carro, CGarcía, PGutiérrez, EMacía, MQuintana, LFQuiroga, BSoler, MJTorregrosa, IAcute kidney injuryAcute interstitial nephritisImmune checkpoint inhibitorsImmunotherapyRenal immune-related adverseeffectRenal transplantationThe most widely used approach in the immunotherapy treatment of cancer is the administration of monoclonal antibodies directed against regulatory molecules of immune control that inhibit the activation of T cells, the so-called check point inhibitors (ICI). ICI nephrotoxicity epidemiology and pathology; its diagnosis with or without kidney biopsy; the type and duration of treatment; the possibility of rechallenging after kidney damage; and its indication in patients with cancer and renal transplantation are certainly controversial. In the absence of definitive studies, this document is intended to specify some recommenda-tions agreed by the group of onconephrology experts of the Spanish Society of Nephrology in those areas related to ICI nephrotoxicity, in order to help decision-making in daily clinical practice in onconephrology consultations.(c) 2022 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/18084NEFROLOGIAISSN: 02116995ISSNe: 19892284ISSNl: 20132514reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAEspañolinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p180842026-06-07T16:35:31Z
dc.title.none.fl_str_mv Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
title Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
spellingShingle Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
Alonso, F
Acute kidney injury
Acute interstitial nephritis
Immune checkpoint inhibitors
Immunotherapy
Renal immune-related adverse
effect
Renal transplantation
title_short Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
title_full Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
title_fullStr Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
title_full_unstemmed Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
title_sort Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology
dc.creator.none.fl_str_mv Alonso, F
de Francisco, ALMM
Auñón, P
García-Carro, C
García, P
Gutiérrez, E
Macía, M
Quintana, LF
Quiroga, B
Soler, MJ
Torregrosa, I
author Alonso, F
author_facet Alonso, F
de Francisco, ALMM
Auñón, P
García-Carro, C
García, P
Gutiérrez, E
Macía, M
Quintana, LF
Quiroga, B
Soler, MJ
Torregrosa, I
author_role author
author2 de Francisco, ALMM
Auñón, P
García-Carro, C
García, P
Gutiérrez, E
Macía, M
Quintana, LF
Quiroga, B
Soler, MJ
Torregrosa, I
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Acute kidney injury
Acute interstitial nephritis
Immune checkpoint inhibitors
Immunotherapy
Renal immune-related adverse
effect
Renal transplantation
topic Acute kidney injury
Acute interstitial nephritis
Immune checkpoint inhibitors
Immunotherapy
Renal immune-related adverse
effect
Renal transplantation
description The most widely used approach in the immunotherapy treatment of cancer is the administration of monoclonal antibodies directed against regulatory molecules of immune control that inhibit the activation of T cells, the so-called check point inhibitors (ICI). ICI nephrotoxicity epidemiology and pathology; its diagnosis with or without kidney biopsy; the type and duration of treatment; the possibility of rechallenging after kidney damage; and its indication in patients with cancer and renal transplantation are certainly controversial. In the absence of definitive studies, this document is intended to specify some recommenda-tions agreed by the group of onconephrology experts of the Spanish Society of Nephrology in those areas related to ICI nephrotoxicity, in order to help decision-making in daily clinical practice in onconephrology consultations.(c) 2022 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/18084
url https://incliva.portalinvestigacion.com/publicaciones/18084
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ
publisher.none.fl_str_mv SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ
dc.source.none.fl_str_mv NEFROLOGIA
ISSN: 02116995
ISSNe: 19892284
ISSNl: 20132514
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410688942735360
score 15.812429

Registros relacionados